Between late-stage readouts and regulatory events, the biotech industry has enough second-half catalysts to potentially actualize Cantor Fitzgerald’s investment theses and justify its price targets, according to the firm’s recent note.
The most imminent is Versartis Inc VSAR’s September release of phase 3 data from its somavaratan study, which compares the drug against Pfizer Inc. PFE’s Genotropin in patients with pediatric hormone growth deficiency. Cantor Fitzgerald considers it “achievable” for Versartis to prove non-inferiority, and it projects a 70-percent probability of somavaratan reaching commercialization.
The second catalyst will be bluebird bio Inc BLUE’s December release of initial results from its modified LentiGlobin drug. Cantor Fitzgerald isn’t hopeful for positive outcomes, noting a 15 percent probability of success for the sickle cell treatment.
At another undetermined date, regulatory advisory committees are expected to meet to discuss the biologics license application for Spark Therapeutics Inc ONCE’s Luxturna and new drug application for Aerie Pharmaceuticals Inc AERI’s Rhopressa.
The effects of these will be further compounded by clinical data reports from Abeona Therapeutics Inc ABEO, Bellicum Pharmaceuticals Inc BLCM, Corbus Pharmaceutical Holdings Inc CRBP, Global Blood Therapeutics Inc GBT, Spark Therapeutics Inc, Spring Bank Pharmaceuticals Inc SBPH and Zynerba Pharmaceuticals Inc ZYNE.
The aggregate performances of these players thus far led to a strong first-half for the biotech sector. By the date of publication, iShares NASDAQ Biotechnology Index (ETF) IBB was up 16.5 percent on the year against SPDR S&P 500 ETF Trust SPY’s 9.4 percent.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.